iwCLL 2023 | MIRACLE study: using an MRD-guided strategy to direct treatment duration in previously untreated CLL

In this interview, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, introduces the MIRACLE study (NCT05677919), a Phase II trial of measurable residual disease (MRD)-guided time-limited therapy with a pirtobrutinib and venetoclax combination in patients with previously untreated chronic lymphocytic leukemia (CLL). Dr Wang outlines the protocol of the study, which does not involve an arbitrary period of treatment, but instead permits discontinuation of treatment when patients reach MRD-undetectable status at set time points. MRD status is an important endpoint when treating with time-limited venetoclax-based combination therapies and Dr Wang hopes that this study will elucidate whether an MRD-guided treatment strategy will be feasible and generate high efficacy in CLL patients. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.